Background: Statins have uncertain benefits in persons with chronic kidney disease (CKD)
because individual trials may have insufficient power to determine whether treatment effects …

Dyslipidemia is an established cardiovascular (CV) risk factor in the general population. In
chronic kidney disease (CKD), however, epidemiologic studies (1–3) and clinical trials (4 …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on the screening, monitoring, and …

Aims The effects of statin therapy in patients with chronic kidney disease (CKD) remain
uncertain. We undertook a systematic review and meta-analysis to investigate the effects of …

Cardiovascular disease is a major cause of morbidity and mortality in patients with impaired
renal function. Dyslipidemia has been established as a well-known traditional risk factor for …

Background: Lipid-lowering therapy is not widely used in persons with chronic kidney
disease (CKD) despite a high burden of dyslipidemia and cardiovascular disease in this …

Background: Screening and monitoring for chronic kidney disease (CKD) could lead to
earlier interventions that improve clinical outcomes. Purpose: To summarize evidence about …

Dyslipidemia and the progression of renal disease in chronic renal failure patients
Dyslipidemia is a common complication of progressive kidney disease and contributes to the …

Background The incidence and prevalence of chronic kidney disease (CKD) are increasing
worldwide and are associated with poor outcomes. According to the 1999–2004 National …

Background: Many effects of statins on non–cardiovascular disease (non-CVD) outcomes
have been reported. Purpose: To evaluate the quantity, validity, and credibility of evidence …